Changes in Beneficial Ownership · 4
Evogene Ltd
EVGNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-09-04
- Issuer
- Evogene Ltd.
- Issuer CIK
- 0001574565
- Trading symbol
- EVGN
Reporting owner 1
- Name
- RECANATI LEON
- Reporting owner CIK
- 0000919590
- Relationship
- Director
- Address
- 27 YOAV ST., TEL AVIV, ISRAEL, L3, 6908165
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Ordinary Shares[F1] | 1,343,886[F1] | D |
Table key
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 0.58[F2] | 2026-09-04 | A · Form 4[F3] | 2,500 | A | 0 | [F4] | 2036-09-04 | Ordinary Shares | 2,500 | 2,500 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Amount owned | Ownership |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)[F1] | 54.32 | 2021-06-11 | 2027-05-16 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)[F1] | 32.05 | 2022-06-11 | 2028-06-25 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)[F1] | 17.68 | 2023-06-11 | 2029-07-30 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)[F1] | 12.03 | 2024-06-11 | 2030-11-17 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)[F1] | 39.32 | 2025-06-11 | 2031-06-11 | Ordinary Shares | 250 | 250 | D |
| Stock Option (right to buy)[F1] | 28.62 | 2022-08-10 | 2031-09-01 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)[F1] | 10.5 | 2023-09-15 | 2032-09-15 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)[F1] | 6.03 | 2024-05-11 | 2033-05-11 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)[F1] | 7.16 | 2025-06-13 | 2034-06-13 | Ordinary Shares | 1,800 | 1,800 | D |
| Stock Option (right to buy)[F1] | 1.29 | 2026-08-18 | 2035-08-18 | Ordinary Shares | 2,500 | 2,500 | D |
Table key
- D
- Direct
Footnotes
- F1
- There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12
- F2
- The exercise price of the options to purchase Ordinary Shares of the Issuer (the "Options") reported in this row is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.↩ 1
- F3
- The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options. The Options were granted pursuant to, and are subject to the terms of, the Issuer's 2021 Share Incentive Plan,↩ 1
- F4
- The Options vest and become exercisable on a quarterly basis (25% per quarter), commencing on September 4, 2026, such that the Options will be fully vested on September 4, 2027, the one-year anniversary of the grant date.↩ 1
Remarks
Exhibit 24.1 - Power of Attorney.
Signature 1
- Signed
- /s/ Nitsan Deutsch, Attorney-in-fact
- Date
- 2026-09-29
Filed exhibits
- EXHIBIT 24.1 ↗ex24-1.htm